ZYBERNO
Stock Report
Updated Aug 30, 2026

Arcus Biosciences, Inc. (RCUS)

Healthcare • NYSE

$29.21

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
22.0/100
POOR BUSINESS
Arcus Biosciences, Inc. (RCUS) scores 22/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-89.5%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.24x)
Operating Margin (Operational Efficiency):CRITICAL (-415.4%)
Return on Capital (Capital Efficiency):CRITICAL (-65.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Arcus Biosciences, Inc. (RCUS) stock report — Zyberno Score 22/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, RCUS generated -$489.00M in Owner Earnings. Capital was deployed as follows: $1.00M invested in capital expenditures. Reinvestment rate: 2.2%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:29.21
Market Cap:$3.68B

Valuation Multiples (3)

P/B Ratio:7.94x
P/S Ratio:31.48x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$3.78B

Price Action & Momentum (3)

Momentum Percentile:98 / 100
% of 52-Week High:92.0%
B. Profitability Assessment

Return Metrics (5)

ROA:-45.6%
Reinvestment Rate:2.2%
Fundamental Growth Rate (g):-1.4%

Margin Analysis (3)

Operating Margin Ttm:-415.4%
Net Margin Ttm:-393.2%
Ebitda Margin:-407.7%

TTM Performance (2)

Operating Margin Ttm:-415.4%
Net Margin Ttm:-393.2%

Yield Metrics (2)

Earnings Yield:-$13.32
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-1,218.4%
Latest Earnings Filed:2026-08-05

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-10.1%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.82x
Quick Ratio:3.82x
Cash Ratio:0.76x

Leverage Analysis (3)

Debt To Equity Ttm:0.24x
Debt-to-Equity Ratio:0.24x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-35.09x
Times Interest Earned:-35.09

Capital Structure (4)

Working Capital:558,000,000.00
Cash And Cash Equivalents:150,000,000.00
Long Term Debt:$101.00M
Net Debt:$96.00M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $117.00M
Linear Growth: -10.1%
📊 Click to view full RCUS Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$486.00M

Bottom Line Performance (3)

-$460.00M
Income Before Tax:-$460.00M
Ebitda Ttm:-477,000,000.00

Operating Expenses (5)

Operating Expenses:603,000,000.00
R And D Expense:497,000,000.00
Sga Expense:106,000,000.00
Income Tax Expense:$0.00
Interest Expense:11,000,000.00

Expense Ratios (3)

R And D To Revenue Percentage:1,212.2%
Sga To Revenue Percentage:258.5%
Ebitda Margin:-407.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$924.00M
Current Assets:$756.00M
Ppe Net:36,000,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:460,000,000.00
Current Liabilities:198,000,000.00
Long Term Debt:$101.00M
Short Term Debt:$145.00M

Equity & Capital (3)

Equity:$464.00M
Retained Earnings:-$1.70B
Common Stock:2,169,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:34,000,000.00

Special Items (2)

Contract Liabilities:56,000,000.00
Stock Based Compensation:15,000,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$488.00M-$489.00M

Investment Activities (2)

Investing Cash Flow:$114.00M
Capital Expenditures Ttm:1,000,000.00

Financing Activities (3)

Financing Cash Flow:$3.00M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$49.00M
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:9,000,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.89
-$3.89
Earnings Per Share Ttm:-$3.65

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.93
Operating Cash Flow Per Share:-$3.82

Book Value & Capital (2)

Book Value Per Share:$3.68
Cash Per Share:1.19

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.12x
Working Capital Turnover Ttm:0.21x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:106.07
Cash Conversion Cycle:-2,104.07
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$489.00M

Damodaran Growth Analysis (2)

Reinvestment Rate:2.2%
Fundamental Growth Rate (g):-1.4%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-10.1%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-8.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:RCUS
Company Name:Arcus Biosciences, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:126.10M
Shares Outstanding Basic:126.10M
Shares Outstanding Diluted:126.10M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 21:11:51 UTC
Data Timestamp:2026-08-30T21:11:51.873733
Scroll to Top